Trial
NCT01473758
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Intervention
Roflumilast
Why stopped
Company decision: No Safety or Efficacy Concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-14